Tumor response rates after initial treatment with peptide receptor radionuclide therapy have proven clinical benefit; however, complete response is uncommon.
Mathew Shanley
Advertisement
Articles by Mathew Shanley
Encouraging results are being seen following the administration of cabozantinib (Cabometyx) in patients with carcinoid and pancreatic neuroendocrine tumors. Clinical benefit of the drug has been exhibited in patients enrolled in a prospective phase II trial, which was initiated in July 2012; however, a randomized phase III trial will be necessary for confirmation.
Advertisement
Latest Updated Articles
Phase III Trial Needed to Confirm Clinical Benefit of Cabozantinib in Carcinoid and Pancreatic NETsPublished: October 20th 2017 | Updated:
- PRRT Effective and Safe as Salvage Therapy for GEP and Bronchial NETs
Published: October 21st 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
